



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number : **0 334 538 B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification :
02.12.92 Bulletin 92/49

(51) Int. Cl.⁵ : **C07C 217/54, C07C 321/24,
C07D 333/20, A61K 31/135**

(21) Application number : **89302533.8**

(22) Date of filing : **15.03.89**

(54) **Therapeutically useful tetralin derivatives.**

Consolidated with 89903628.9/0407416
(European application No./publication No.) by
decision dated 19.09.91.

(30) Priority : **25.03.88 US 173130**

(43) Date of publication of application :
27.09.89 Bulletin 89/39

(45) Publication of the grant of the patent :
02.12.92 Bulletin 92/49

(84) Designated Contracting States :
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited :
EP-A- 0 168 505
JOURNAL OF PHARMACEUTICAL SCIENCES,
vol. 67, no. 6, June 1978; A.T.DREN et al., pp.
880- 882.
AUSTRALIAN JOURNAL OF CHEMISTRY, vol.
20, 1967; D.M.TEMPLE, pp. 601-604.

(73) Proprietor : **THE UPJOHN COMPANY**
301 Henrietta Street
Kalamazoo, Michigan 49001 (US)

(72) Inventor : **Andersson, Bengt Ronny**
Floravagen 3H
S-43700 Lindome (SE)
Inventor : **Carlsson, Per Arvid Emil**
Torid Wulffsgatan 50
S-41319 Goteborg (SE)
Inventor : **Svensson, Kjell Anders Ivan**
Karrbogarde, PL 3903
S-44165 Alingas (SE)
Inventor : **Wikstrom, Hakan Vilhelm**
Gibsons vag 25
S-43361 Partille (SE)

(74) Representative : **Perry, Robert Edward et al**
GILL JENNINGS & EVERY 53-64 Chancery
Lane
London WC2A 1HN (GB)

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention is related to new 1,2,3,4-tetrahydro-2-naphthylamines, to processes for preparing such compounds, pharmaceutical preparation of such compounds and the use of such compounds in manufacture of a pharmaceutical preparation.

In depressed patients evidence indicates the neurotransmission in the central nervous system (CNS) may be disturbed. These disturbances involve the neurotransmitters noradrenaline (NA) and 5-hydroxytryptamine (5-HT). The drugs most frequently used in the treatment of depression are considered to act by improving the neurotransmission of either or both of these physiological agents. Available data suggests that the enhancement of 5-HT neurotransmission will primarily improve depressed mood and anxiety, whereas the enhancement of noradrenaline neurotransmission will improve retardation symptoms occurring in depressed patients. In recent years many efforts have been made to develop new drugs with high selectivity for the improvement of the 5-HT neurotransmission in the CNS.

The mechanism of action for the drugs generally used today in the therapy of mental depression is generally believed to be indirect with the drugs acting by blocking the reuptake of the neurotransmitters, NA and/or 5-HT, released from nerve terminals in the CNS, which increases the concentration of these transmitters in the synaptic cleft and restores an adequate neurotransmission. For example, the clinically documented antidepressant drug, zimelidine (dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl)propene) acts as such a reuptake inhibitor with high selectivity for 5-HT neurons.

A fundamentally different way to improve the neurotransmission in the central 5-HT neurons would be to use a 5-HT receptor agonist acting directly upon the 5-HT receptors, and particularly the 5-HT_{1A} receptor. In order to minimize undesired side effects, a high selectivity for this kind of receptor would be necessary.

Clinically, 5-HT_{1A} agonists have also demonstrated anxiolytic properties. The drug, Buspirone, is the only currently available marketed 5-HT_{1A} agonist having anxiolytic activity. This compound antagonizes dopamine receptors at the same dose it stimulates 5-HT_{1A} receptors. A similar drug, Gepirone, also has dopamine antagonist properties. These dopamine antagonist properties reduce the clinical utility of these compounds however because long term treatment with dopamine antagonists can produce tardive dyskinesia.

The search for new CNS active compounds is focused on finding compounds with selective 5-HT_{1A} receptor agonist effects without detrimentally influencing central dopamine receptors.

Drugs acting on central dopamine transmission are clinically effective in treating a variety of central nervous system disorders such as parkinsonism, schizophrenia, and manic-depressive illness. In parkinsonism, for example, the nigro-neostriatal hypofunction can be restored by an increase in postsynaptic dopamine receptor stimulation. In schizophrenia, the condition can be normalized by achieving a decrease in postsynaptic dopamine receptor stimulation. Classical antipsychotic agents directly block the postsynaptic dopamine receptor. The same effect can be achieved by inhibition of intraneuronal presynaptic events essential for the maintenance of adequate neurotransmission, transport mechanism and transmitter synthesis.

In recent years a large body of pharmacological, biochemical and electrophysical evidence has provided considerable support in favor of the existence of a specific population of central autoregulatory dopamine receptors located in the dopaminergic neuron itself. These receptors are part of a homeostatic mechanism that modulates nerve impulse flow and transmitter synthesis and regulates the amount of dopamine released from the nerve endings.

Direct dopamine receptor agonists, like apomorphine, are able to activate the dopamine autoreceptors as well as the post synaptic dopamine receptors. The effects of autoreceptor stimulation appear to predominate when apomorphine is administered at low doses, whereas at higher doses the attenuation of dopamine transmission is outweighed by the enhancement of postsynaptic receptor stimulation. The antipsychotic and antidyskinetic effects in man of low doses of apomorphine are likely due to the autoreceptor-stimulator properties of this dopamine receptor agonist. This body of knowledge indicates dopamine receptor stimulants with a high selectivity for central nervous dopamine autoreceptors would be valuable in treating psychiatric disorders.

The following documents could be important in the examination of this application.

Derwent 12191K (Belgium 893,917) discloses indanyl substituted imidazole derivatives and tetralyl imidazole derivatives wherein the aromatic ring of the indanyl and tetralyl groups may be substituted with various groups including halogen, alkyl (C₁-C₆), trihaloalkyl, alkoxy and alkylthio. The compounds are useful in treating atherosclerosis.

British Patent 1,377,356 discloses 8-hydroxy and 8-methoxy substituted-1,1-dialkyl-2-aminotetralins wherein the amino group is unsubstituted or substituted with an alkyl C₁-C₆. These compounds are useful as analgesics.

Derwent 40378A/23 (British 1,597,140) discloses, among other compounds, 2-aminotetralins substituted on the aromatic ring with halogen, di-chloro and additionally hydroxy or an alkanoyloxy group. These com-

pounds are useful in treating heart conditions and/or Parkinson's disease.

Switzerland 637,363 (Derwent 729,386) and Switzerland 637,364 discloses, among other compounds, 2-aminotetralins substituted on the aromatic ring with halogen, di-chloro and additionally hydroxy, alkyl or other functional groups. These compounds are stimulants of α - and β -adrenergic and dopamine receptors rendering them useful in treating heart failure, cardiac infarct, hypertension and Parkinson's disease.

Germany 2,333,847 (Derwent 7633V) discloses a very broad scope of compounds which can include amino tetralins and amino indanes substituted on the aromatic ring with alkoxy or halogen and additionally hydroxy, aralkyloxy or acyloxy. These compounds are water softening agents and corrosion inhibitors in lubricants as well as CNS-depressants and anti-arrhythmics.

European 272,534-A (Derwent) discloses 2-aminotetralins substituted in the 8-position by halogen (fluorine, chlorine, bromine or iodine) among many other compounds within a broad disclosure. These compounds are useful serotonin antagonists or agonists with high affinity for cerebral 5-HT₁ receptors rendering them useful in the treatment of CNS disorders, cognitive deficiencies, Alzheimer's disease, cardiovascular disorders, pain and intestinal disorders.

German 2803582 (Derwent 58247B) discloses 2-aminotetralins wherein the amino group is substituted with inter alia alkyl, or cycloalkyl and wherein the aromatic ring is substituted with inter alia alkyl, halogen, di-chloro and additionally with hydroxy or an alkanoyloxy group. These compounds have a stimulant effect on α - and β -adrenoreceptors and on dopamine receptors and are useful in the treatment of heart failure, cardiac infarct, elevated blood pressure and Parkinson's disease.

Wikstrom, H., et al., J. Med. Chem. 30, 1115 (1987) discloses 4-hydroxy- and 4-methoxy-2-aminoindanes wherein the amino moiety is unsubstituted or is substituted with dimethyl or di-n-propyl; 5-hydroxy-2-dimethylaminoindane; and 7-hydroxy-2-aminotetralin wherein the amino moiety is substituted with dimethyl or di-n-propyl. This paper focuses on the conformational analysis of the compounds in relation to their central dopaminergic effects.

J.G. Canon, et al., J. Med. Chem. 25, 1442-1446 (1982) and J. Med. Chem. 28, 515-518 (1985) disclose inter alia, 4-hydroxy- and 5-hydroxy-2-di-n-propylindane in a study dealing with the conformational analysis of a series of 2-aminoindans.

Seeman, et al., Molecular Pharmacology 28, 291-299 (1985) includes a number of known hydroxy substituted and methoxy substituted aminotetralins and aminoindans in a D₂ receptor binding affinity study.

A.T. Dren, et al., J. Pharm. Sci. 67, 880-882 (1978) discloses among other compounds 2-aminotetralin wherein the amino group is mono-substituted with cyclopropylmethyl or cyclopropyl and the aromatic ring is substituted with methoxy at the 5- or 6-position. These compounds were tested for local anesthetic activity.

D.E. Ames, et al., J. Chem. Soc. 2636 (1965) describes the synthesis of various di-alkoxy substituted aminotetralins wherein the alkoxy groups have from 1 to 4 carbon atoms. 6-Methoxy-2-aminotetralin is also described.

L.E. Arvidsson, J. Med. Chem. 27, 45-51 (1984) describes a series of 2-aminotetralins wherein the amine is substituted with one or two lower alkyl groups of 1-4 carbon atoms, octyl or benzyl, and the aromatic ring is substituted 5- and/or 8-position with hydroxy or lower alkoxy. These compounds were tested as dopamine and 5-hydroxytryptamine receptor agonists.

L.E. Arvidsson, et al., J. Med. Chem. 24, 921-923 (1981) discloses 8-methoxy-2-aminotetralins wherein the amino moiety is substituted with n-propyl, benzyl or di-n-propyl and 2-di-n-propylaminotetralins wherein the aromatic ring is substituted in the 5-, 6-, 7- or 8-position with hydroxy. These compounds were evaluated for their effect on dopaminergic and α -adrenergic receptors.

J.D. McDermid, et al., J. Med. Chem. 19, 547-549 (1976) discloses 5,6-dihydroxy and 5-, 6- and 7-hydroxy-2-di-n-propylaminotetralins in a study of their dopaminergic activity.

J.D. McDermid, et al., J. Med. Chem. 18, 362-367 (1975) discloses a large series of 2-aminotetralins wherein the aromatic ring is mono- or di-substituted with hydroxy, methyl or lower alkoxy and the amine moiety is unsubstituted or substituted with lower alkyl, benzyl, alkoxyalkyl or forms part of a monocyclic heterocyclic group. These compounds were evaluated for their dopaminergic activity.

L.E. Arvidsson, J. Med. Chem. 30, 2105-2109 (1987) evaluates the 5-HT receptor agonist activity of 1-methyl-2-di-n-propylaminotetralins substituted in the 8-position with hydroxy or methoxy.

D.B. Rusterholz, et al., J. Med. Chem. 19, 99-102 (1976) discloses 5- and/or 8-substituted-2-aminotetralins wherein the 5- or 8- position is substituted with methyl, hydroxy or methoxy. The effect of these compounds on prolactin release is evaluated.

J.G. Cannon, et al., J. Med. Chem. 28, 515 (1985) describes the resolution of 4-hydroxy-2-(di-n-propyl)aminoindane, a synthetic precursor to a potent dopaminergic agonist.

This invention encompasses compounds of Formula I and pharmaceutically acceptable acid addition salts thereof, wherein -YR₁ is one substituent on the 5, 6, 7 or 8 position of the aromatic ring and is -S(1-C₃)alkyl or

-OR₁ wherein R₁ is selected from (C₁-C₈) alkyl, (C₁-C₈) alkenyl, -CH₂-(C₃-C₈) cycloalkyl or benzyl; wherein R₂ is hydrogen or (C₁-C₃) alkyl; wherein R₃ is -CH₂-(C₃-C₈) cycloalkyl; wherein R₄ is hydrogen, (C₁-C₈) alkyl, -CH₂-(C₃-C₄) cycloalkyl, -(CH₂)_m-R₅ or -CH₂CH₂-X-(CH₂)_nCH₃; wherein n is zero to 3 and m is 2 or 3; wherein X is oxygen or sulfur; and wherein R₅ is 2-thiophenyl, 3-thiophenyl, phenyl or phenyl substituted with one or two substituent groups selected from chlorine, bromine, fluorine, (C₁-C₃)alkoxy, or (C₁-C₃)alkyl; with the proviso that when R₃ contains more than 4 carbon atoms and R₄ is alkyl said alkyl contains from one to 3 carbon atoms.

The compounds of this invention possess selective pharmacological properties and are useful in treating central nervous system disorders including antidepressant symptoms, anxiolytic symptoms, panic attacks, obsessive-compulsive disturbances, senile dementia, emotional disturbances related to dementia disorders, and stimulation of sexual activity. The compounds of this invention are also useful to alleviate aggressive behavior, confusional delirious states and impotence. Certain compounds of this invention additionally possess blood pressure lowering affects. Processes for preparation of these compounds, their pharmaceutical use and pharmaceutical preparations employing such compounds constitute further aspects of the invention.

According to a preferred embodiment the invention is related to compounds of Formula I wherein R₃ is -CH₂-(C₃-C₈) cycloalkyl, R₄ is (C₁-C₈) alkyl or -CH₂-(C₃-C₄) cycloalkyl and R₁ is a methyl group. A more preferred embodiment are compounds of Formula I wherein R₃ is cyclopropylmethyl, R₄ is (C₁-C₄) alkyl or cyclopropylmethyl and R₁ is a methyl group.

An object of the invention is to provide compounds for therapeutic use, especially compounds having a therapeutic activity in the central nervous system. Another object is to provide compounds having an effect on the 5-HT_{1A} receptor in mammals including man. A further object of this invention is to provide compounds having an effect on the subclass of dopamine receptors known as the D₂ receptor.

The compounds of this invention are identified in two ways: by the descriptive name and reference to labelled structures contained in appropriate charts. In appropriate situations, the proper stereo-chemistry is also represented in the charts.

In this document the parenthetical term (C_n-C_m) is inclusive such that a compound of (C₁-C₈) would include compounds of one to 8 carbons and their isomeric forms. The various carbon moieties are defined as follows: Alkyl refers to an aliphatic hydrocarbon radical and includes branched or unbranched forms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, and n-octyl.

Alkoxy as represented by -OR₁ when R₁ is (C₁-C₈) alkyl refers to an alkyl radical which is attached to the remainder of the molecule by oxygen and includes branched or unbranched forms such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentoxy, isopentoxy, neo-pentoxy, n-hexoxy, isohexoxy, n-heptoxy, isoheptoxy, and n-octoxy.

Alkenyl refers to a radical of an aliphatic unsaturated hydrocarbons having a double bond and includes both branched and unbranched forms such as ethenyl, 1-methyl-1-ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-4-pentenyl, 3-methyl-1-pentenyl, 3-methyl-2-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 1-methyl-4-hexenyl, 3-methyl-1-hexenyl, 3-methyl-2-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-methyl-4-heptenyl, 3-methyl-1-heptenyl, 3-methyl-2-heptenyl, 1-octenyl, 2-octenyl, or 3-octenyl. Cycloalkyl refers to a radical of a saturated cyclic hydrocarbon such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

It will be apparent to those skilled in the art that compounds of this invention may contain chiral centers. The scope of this invention includes all enantiomeric or diastereomeric forms of Formula I compounds either in pure form or as mixtures of enantiomers or diastereomers. The compounds of Formula I contain two asymmetric carbon atoms in the aliphatic ring moiety, including the ring carbon atoms adjacent to the nitrogen atom. The therapeutic properties of the compounds may to a greater or lesser degree depend on the stereo-chemistry of a particular compound. Pure enantiomers as well as enantiomeric or diastereomeric mixtures are within the scope of the invention.

Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds of this invention. Illustrative acids are sulfuric, nitric, phosphoric, hydrochloric, citric, acetic, lactic, tartaric, palmoic, ethanedisulfonic, sulfamic, succinic, cyclohexylsulfamic, fumaric, maleic, and benzoic acid. These salts are readily prepared by methods known in the art.

The compounds of this invention may be obtained by one of the following methods described below and outlined in the appropriate charts. A compound of the formula, C-1, may be converted into a compound of Formula I, when R₁ and R₄ are the same, by alkylation of the nitrogen and oxygen atoms with an appropriate alkylating agent. The compound of the formula, C-1, may be treated with an alkyl-halide or tosylate of the formula R_aX, when R_a is alkyl or cycloalkyl, and when X is Cl, Br, I or TsO, in an organic solvent such as acetonitrile or acetone and in the presence of a base such as potassium carbonate or sodium hydroxide.

Alternatively, the compounds of this invention may be obtained from a compound of the formula, C-2, by alkylation of the hydroxy moiety with an appropriate alkylating agent. The starting compound, C-2, may be treated with an alkyl halide or tosylate R_bX , when R_b is alkyl, alkenyl, cycloalkyl, or benzyl, when X is Cl, Br, I or TsO, in an organic solvent such as acetonitrile or acetone and in the presence of a base such as potassium carbonate or sodium hydroxide.

In addition, a compound of the formula, C-3, may be converted into a compound of Formula I, by alkylation of the nitrogen atom with an appropriate alkylating agent. The starting compound may be treated with an alkyl halide or tosylate R_cX , when R_c is alkyl, cycloalkyl, heterocyclic alkyl, ethylalkoxy or ethylthiaalkyl, when X is Cl, Br, I or TsO, in an organic solvent such as acetonitrile or acetone and in the presence of a base such as potassium carbonate or sodium hydroxide, or the starting compound, C-3, may be treated with a carboxylic acid sodium borohydride complex, when the carboxylic acid is $HOOC-(C_1-C_7)alkyl$, $HOOC-(C_3-C_8)cycloalkyl$, $HOOC-(CH_2)_p-R_5$, or $HOOC-CH_2-X-(CH_2)_n-CH_3$, when p is one or 2, n is zero to 3 and X is oxygen or sulfur. Alternatively, the starting compound, C-3, may be dissolved in methanol and treated with an aldehyde and sodium cyanoborohydride, when the aldehyde is $HOC-(C_1-C_7)alkyl$, $HOC-(C_3-C_8)cycloalkyl$, $HOC-(CH_2)_p-R_5$, or $HOC-CH_2-X-(CH_2)_n-CH_3$, when p is one or 2, n is zero to 3 and X is oxygen or sulfur.

In addition, an amide of the formula, C-4, when R_d is $(C_1-C_7)alkyl$, $(C_3-C_8)cycloalkyl$, $(CH_2)_p-R_5$, or $-CH_2-X-(CH_2)_n-CH_3$, when p is one or 2, n is zero to 3 and X is oxygen or sulfur, may be reduced by a hydride reducing agent such as lithium aluminium hydride in ether or tetrahydrofuran, diborane in tetrahydrofuran or QBH_4 (where Q represents tetrabutylammonium ion) in a mixture of dichloromethane and dichloroethane, to give a compound of Formula I. Compounds of this invention wherein R_1Y is $-S(C_1-C_3)alkyl$ can be prepared from a compound corresponding to a C-4 compound wherein OR_1 is replaced by a hydroxy group by converting the hydroxy group to an amine which is subsequently converted to bromine via a Sandmeyer reaction. The bromine substituted intermediate is lithiated using n-butyllithium in THF or ether and quenched with $(C_1-C_3)alkyl-SS-alkyl(C_1-C_3)$ to the alkylthio substituted compounds.

Starting materials for the compounds, C-1 to C-4, may be obtained by the methods described below or by methods known in the art. The known or commercially available ketone, C-5, when R_1 is alkyl, alkenyl, cycloalkyl, or benzyl, reacts with hydroxylamine in the presence of base to give the intermediate oxime which is reduced by catalytic hydrogenation to a compound of formula, C-6. To obtain the secondary amine a compound of the formula, C-6, is acylated with a carboxylic acid chloride in the presence of triethylamine and subsequently reduced by a hydride reducing agent such as lithium aluminum hydride in ether or tetrahydrofuran, diborane in tetrahydrofuran or QBH_4 (where Q represents tetrabutylammonium ion) in a mixture of dichloromethane and dichloroethane. Alternatively, the ketone, C-5, can be converted directly to the secondary amine, C-6, by reacting the ketone with a primary amine of the formula R_e-NH_2 , when R_e is alkyl, cycloalkyl, heterocyclic alkyl, ethylalkoxy or ethylthiaalkyl, with sodium cyanoborohydride in methanol acidified to about pH 5 with the addition of a few drops of concentrated acetic acid.

The preparation of the compounds of this invention with an alkyl group at the one position of the aliphatic ring are obtained by alkylating a compound of formula, C-7, either via the enamine or by direct alkylation of the ketone, C-7, under basic conditions, to give a compound of formula, C-5, converting compound, C-5, into the secondary amine using methods already described, separation of the cis- and trans- isomers formed, and finally converting the secondary amine into the tertiary amine using methods already described.

A pure enantiomer of compound, C-3, may be prepared by converting the cis-secondary amine, C-3, into the (-)-O-methylmandelic acid amide, C-8, followed by chromatographic separation of the two diastereomers and cleavage by subsequent reaction with potassium tert-butoxide in tetrahydrofuran with traces of water and methyl lithium. The secondary amine can be converted into the tertiary amine using methods already described.

In clinical practice the compounds of the present invention will normally be administered orally, rectally, or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or as a pharmaceutically acceptable non-toxic, acid addition salt, such as the hydrochloride, lactate, acetate, sulfamate salt, in association with a pharmaceutically acceptable carrier. The use and administration to a patient to be treated in the clinic would be readily apparent to a person of ordinary skill in the art.

In therapeutic treatment the suitable daily doses of the compounds of the invention are 1-2000 mg for oral application, preferentially 50-500 mg, and 0.1-100 mg for parenteral application, preferentially 0.5-50 mg.

The compounds of this invention where $-OR_1$ is in the 8 position in the aromatic ring are very selective 5-HT_{1A} receptor agonists having little or no dopaminergic activity. The IC₅₀ ratio of dopamine D₂ to 5-HT_{1A} in vitro binding data shown in Table 1 for one compound of this invention, 8-methoxy-2-(N,N-dicyclopropylmethyl)-tetralin, demonstrates the selectivity for the 5-HT_{1A} receptor. These compounds are particularly effective anxiolytic and anti-depressant agents. Other uses for these compounds include panic attacks, obsessive-compulsive disturbances, and senile dementia particularly the emotional disturbances seen in dementia disorders. In ad-

dition, central 5-HT receptor activation are believed to be involved in mediating sexual behavior. These compounds would be useful to stimulate sexual activity and to alleviate impotence.

The compounds of this invention where -OR₁ is in the 5-, 6-, or 7-position show selective affinity for D₂ receptors. These compounds are particularly effective in treating psychoses, manic-depressive illness and parkinsonism.

The compounds of this invention also have been shown to have high oral potency and a long duration of action. Both these features are beneficial to effective clinical treatment.

The utility of the compounds of this invention to treat central nervous system disorders is shown in behavioral and biochemical activity in reserpine-pretreated rats.

Antagonism of the reserpine-induced "neuroleptic syndrome" in the rat (gross behavior).

Depletion of the monoamine stores with reserpine brings about a "neuroleptic syndrome" characterized by hypomotility, catalepsy, muscle rigidity, hunch-backed posture as well as a number of other central and peripheral signs of monoamine depletion. The whole or parts of this syndrome can be reversed by the administration of drugs that stimulate dopamine or 5-HT receptors directly or indirectly.

Stimulation of the dopamine receptors, with apomorphine for example, gives rise to both locomotion and stereotyped behavior such as sniffing, gnawing and jumping. On the other hand, stimulation of the 5-HT receptors, with 5-hydroxytryptophan (5-HTP) combined with MAO-inhibitors for example, gives rise to a very different behavior. The animals lie flat on the cage floor exhibiting forward movements with extended forepaws padding, "piano-playing," and abducted hindlegs, occasionally with some tremor in the forebody and with Straub tail, stiff tail erection.

In-vivo determination of rat brain tyrosine and tryptophan hydroxylation after reserpine pretreatment (biochemically monitored dopamine and 5-HT receptor activity).

The compounds evaluation were tested biochemically for central dopamine and 5-HT receptor (pre- and/or postsynaptic) stimulating activity. The concept of this biochemical screening method is that a dopamine or 5-HT-receptor agonist will stimulate the receptor and through regulatory feedback systems effect a decline in tyrosine or tryptophan hydroxylating activity, respectively, and a subsequent reduction in the synthesis rate for dopamine and 5-HT in the presynaptic neuron. Dopamine and 5-HTP formation, as determined after in-vivo inhibition of the aromatic L-amino acid decarboxylase with NSD 1015 (3-hydroxybenzylhydrazine hydrochloride) are taken as indirect measures of dopamine and 5-HT-synthesis rates, respectively.

Analogous conditions probably exist also for central NA-neurons. Effects on the dopamine formation in the NA-predominated hemispherical parts (mainly cortex) may thus be considered to reflect NA-receptor-mediated changes.

Experimental procedures.

Rats (150-300 g) pretreated with reserpine (5 mg/kg, 18 hours before) were given the test compounds. Gross behavioral observations (changes in motility, hindleg abduction, etc.) were made. Subsequent administration of NSD 1015, decapitation, brain dissection (corpora striata, the limbic forebrain and the remaining hemispherical portions (mainly cortex) or rat brain), homogenization, centrifugation, ion-exchange chromatography and spectrofluorimetric measurements (all as described in detail by Wikstrom, et al., J. Med. Chem., 21, 864-867, 1978 and reference cited therein), or by HPLC/EC, gave the actual dopamine and 5-HTP levels. Several doses (n=4-6) were tested for each compound and brain area. The dose of a compound giving 50% of the maximal reduction of the %-HTP level in the rat brain part was then estimated. These ED₅₀ values are presented in Table I.

All the compounds in Table 1 were behaviorally and biochemically active, producing the above mentioned effects indicating either central dopamine or 5-HT receptor stimulation. The absence of significant decreases in the dopamine levels in the hemispherical brain parts suggests that none of the compounds possess central NA receptor stimulating effects at the dosage under consideration.

Certain compounds of the present invention also demonstrate blood pressure lowering effects, e.g., the compounds of Examples 12, 13, and 17 when measured in spontaneously hypertensive rats as described by Grodin, et al., J. Pharm. Pharmacol. 37, 263-265 (1984). Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding dis-

closure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

Example 1

8-Methoxy-2-(N-cyclopropylmethylamino)tetralin

8-Methoxy-2-aminotetralin hydrochloride (0.5 g, 2.35 mmol) is dissolved in dichloromethane (50 ml), and triethylamine (3 ml) and cyclopropanecarboxylic acid chloride (0.95 ml) are added. The reaction is stopped after 2 hours by the addition of 10% sodium carbonate (50 ml). The organic layer is separated, washed with water (50 ml), dried over sodium carbonate, filtered and the solvent is evaporated yielding the amide as an oil (0.85 g). The amide is dissolved in dichloromethane (25 ml) and reduced with the addition of dichloroethane (25 ml) and QBH_4 (2.5 g) (where Q denotes the tetrabutylammonium ion) under reflux for 6 hours. The reaction is stopped by the addition of 10% sodium carbonate (100 ml) and dichloromethane (2 x 100 ml). The organic layer is separated, washed with water (50 ml) dried (sodium carbonate), filtered and the solvent evaporated yielding the amine (95% purity according to GC analysis) as an oil (0.47 g). This amine is converted to the hydrochloride salt with the aid of hydrochloric acid-saturated ethanol and evaporation. Recrystallization from ethanol/ether gives white crystals (0.38 g) melting at 214°C. GC/MS shows M^+ as the base peak at $m/e=231.10$. Other prominent peaks appear at $m/e=161.05$ (m-cyclopropylmethylamine; 48.8%), $m/e=160.05$ (53.2%) and $m/e=159.05$ (37.3%).

Example 2

8-Methoxy-2-(N,N-di-cyclopropylmethylamino)tetralin

8-Methoxy-2-(N-cyclopropylmethylamino)tetralin hydrochloride (0.36 g, 1.35 mmol) is dissolved in dichloromethane (50 ml), and triethylamine (1 ml) and cyclopropanecarboxylic acid chloride (0.35 ml) are added. The reaction is stopped after 2 hours by the addition of 10% sodium carbonate (50 ml). The organic layer is separated, washed with water (50 ml), dried (sodium carbonate), filtered and the solvent is evaporated leaving the amide as an oil (0.47 g), which is dissolved in dichloromethane (25 ml) and reduced with the addition of dichloroethane (25 ml) and QBH_4 (2.5 g) (where Q denotes the tetrabutylammonium ion) under reflux for 2 hours. The reaction is not complete at this time according to GC analysis, and further addition of QBH_4 (2.5 g) and dichloroethane (25 ml) is made. The reaction is stopped after one night's reflux by the addition of 10% sodium carbonate (100 ml) and dichloromethane (2 x 100 ml). The organic layer is separated, washed with water (50 ml), dried (sodium carbonate), filtered and the solvent is evaporated yielding the amine as an oil (0.40 g). The amine is chromatographed (silica gel, 40 g) eluting first with petroleum ether:ether (3:1) and then with ether. The fractions containing pure product are pooled and the solvent is evaporated. The residual amine is converted into the hydrochloride by the addition of hydrochloric acid-saturated ethanol and evaporation. Recrystallization from ethyl acetate/ether gives white crystals (114 mg) melting at 174-176°C. GC/MS shows M^+ at $m/e=285.25$ (54.8%), the base peak at $m/e=136.10$. Other prominent peaks appear at $m/e=244.15$ (m-cyclopropyl; 25.0%), $m/e=161.05$ (m-(di-cyclopropylmethylamine); 63.5%).

The remaining fractions are collected and the solvent is evaporated yielding 150 mg of an oil holding 70% of the intermediate amide. The oil is dissolved in dry ether (10 ml) and reduced with lithium aluminum hydride and converted into the hydrochloride salt as described above and recrystallization as above gives 126 mg of white crystals with the same characteristics as those obtained initially.

Example 3

cis-5-Methoxy-1-methyl-2-(N-cyclopropylmethylamino)-tetralin

To a solution of 5-methoxy-1-methyl-2-tetralone (2.0 g) in absolute ethanol (50 ml) are added acetic acid (1.9 g), cyclopropylmethylamine (2.0 g) and 4 Å molecular sieves. The mixture is heated in a closed flask at 80°C for one hour. The molecular sieves are filtered off and the solution is hydrogenated (PtO_2) at atmospheric pressure. The catalyst is filtered off (Celite) and the volatiles are evaporated. Dilute hydrochloric acid (50 ml) is added to the solid residue. The resulting acidic solution is washed with ether, made basic 5% sodium hydroxide and extracted twice with ether. The ether extracts are combined, dried (sodium sulfate) and evaporated. The resulting crude base is eluted through an alumina column with ether-light petroleum (1:4).

Example 4

cis-5-Methoxy-1-methyl-2-(N,N-dicyclopropylmethylamino)tetralin hydrochloride

- 5 Cyclopropanecarboxylic acid chloride (0.49 g) in dry ether (10 ml) is added to a solution of cis-5-methoxy-1-methyl-2-(N-cyclopropylmethylamino)tetralin (400 mg) and triethylamine (0.49 g) in dry ether (80 ml). After 30 minutes at room temperature the reaction mixture is filtered and the ether is evaporated. The resulting crude amide is passed through an alumina column eluted with ether. The purified amide dissolved in dry THF (20 ml) is added to a suspension of lithium aluminum hydride (1.0 g) in dry THF (30 ml) under N₂. After stirring
10 under reflux for 3 hours, the reaction mixture is hydrolyzed, the precipitate is filtered off and the solvent is evaporated. The oily residue is chromatographed on an alumina column with ether-light petroleum (1:1). The hydrochloride is prepared and recrystallized from ethanol-ether to give the title compound.

Example 5

15

(+) and (-)-cis-5-Methoxy-1-methyl-2-(N,N-dicyclopropylmethylamino)tetralin hydrochloride

(-)-cis-5-Methoxy-1-methyl-2-(N,N-dicyclopropylmethylamino)tetralin hydrochloride

- 20 R-(-)-O-Methylmandelic acid chloride (4.1 g), prepared from R-(-)-O-methylmandelic acid by treatment with thionylchloride at 20°C for 10 hours, dissolved in dichloromethane (5 ml) is added at room temperature to a stirred mixture of (±)-cis-5-methoxy-1-methyl-2-(N-cyclopropylamino)tetralin (3.0 g), dichloromethane (25 ml), water (25 ml) and 5% aqueous sodium hydroxide (12 ml). After stirring for 1.5 hour the phases are separated and the organic phase is washed once with water then dried (magnesium sulfate), filtered and evaporated.
25 Ether (15 ml) is added to the residue and one of the diastereomeric amides precipitated (1.2 g). The precipitate is collected by filtration and then recrystallized from acetone to give 1.0 g of one of the diastereomers. The filtrates from the treatment with ether and acetone are combined and evaporated. This oily residue is chromatographed on a silica gel column with ether/light petroleum (50:50). The fractions containing one of the diastereomers, which is eluted first are combined and the solvent is evaporated to give 0.6 g of one of the diastereomeric amides. This diastereomer shows to be the same diastereomeric amide (TLC) as is isolated by precipitation from ether (see above). The diastereomeric amide (1.6 g) is dissolved in dry tetrahydrofuran (40 ml) and kept at -8°C under nitrogen. To this solution is added potassium-tert-butoxide (21.1 g) and water (0.60 ml) with the addition divided in seven portions over 12 days. Thirteen days after the first addition of reagents ice, water and ether is added to the reaction mixture until 2 layers form. The phases are separated and the organic layer
35 is washed with 1M hydrochloric acid, saturated aqueous sodium bicarbonate, dried (magnesium sulfate), filtered and evaporated. The residue, dissolved in ether-light petroleum (50:50), is passed through a silica gel column and eluted first with ether-light petroleum (50:50) and then with ether, yielding a solid (0.55 g) after evaporation. To this solid (0.56 g), dissolved in dry tetrahydrofuran (40 ml) at -8°C and under nitrogen, methyl lithium (0.0054 mol) is added under stirring. The mixture is stirred for 10 minutes, then extracted with saturated aqueous NH₄Cl. The phases are separated and the organic layer is extracted with 5M hydrochloric acid. The combined aqueous layers are made basic with 5M sodium hydroxide and extracted with ether. The organic layer is dried (sodium sulfate) and filtered. Hydrochloric acid-saturated ether is added giving a precipitate which is recrystallized giving (-)-cis-5-methoxy-1-methyl-2-(N-cyclopropylmethylamino)tetralin hydrochloride.
40 Cyclopropanecarboxylic acid chloride (0.28 g) in dry ether (5 ml) is slowly added at 5°C to a solution of (-)-cis-5-methoxy-1-methyl-2-(N-cyclopropylmethylamino)tetralin (0.35 g), triethylamine (0.31 g) and dry ether (45 ml). The mixture is stirred at room temperature for one hour, the triethylammoniumchloride formed is filtered off and the solvent evaporated. The residue (0.40 g) dissolved in dry tetrahydrofuran (10 ml) is added to a suspension of lithium aluminum hydride (0.80 g) in dry tetrahydrofuran (40 ml) under nitrogen. After stirring under reflux for 5 hours, the mixture is hydrolyzed, the precipitate is filtered off, and the solvent is evaporated. The
50 residue is passed through an alumina column with ether/light petroleum (20:80), and the amine is precipitated as the hydrochloride and recrystallized from ethanol-ether to give (-)-cis-5-methoxy-1-methyl-2-(N,N-dicyclopropylmethylamino)tetralin hydrochloride.

Example 6

55

(±)-cis-7-methoxy-1-methyl-2-(N-cyclopropylmethylamino)tetralin

To a solution of 7-methoxy-1-methyl-2-tetralone (2.0 g) in absolute ethanol (50 ml) are added acetic acid

(1.85 g, 31.5 mmol), cyclopropylmethylamine (1.85 g) and 4 Å molecular sieves. The mixture is refluxed for 3.5 hours. The molecular sieves are filtered off and the solution is hydrogenated with 0.3 g PtO₂ in a Parr apparatus. The catalyst is filtered off (Celite) and the volatiles are evaporated. The resulting crude base is eluted through an silica gel column with methanol, affording an oil of 80% isomeric purity (GC). The hydrochloride is prepared and recrystallized 2 times from methanol-ether.

Example 7

(±)-cis-7-methoxy-1-methyl-2-(N,N-dicyclopropylmethylamino)tetralin

Sodium borohydride (0.41 g, 10.1 mmol) is added portionwise to a stirred solution of cyclopropanecarboxylic acid chloride (2.4 g) in dry benzene (20 ml) under N₂, keeping the temperature below 20°C. After 2 hours, (±)-cis-7-methoxy-1-methyl-2-(cyclopropylmethylamino)-tetralin (0.5 g) is added and the mixture is refluxed for 4 hours and then treated with 10% sodium bicarbonate solution. The benzene layer is dried (sodium sulfate) and the solvent is evaporated. The hydrochloride salt is prepared and recrystallized from methanol-ether.

Example 8

Preparation of soft gelatine capsules

500 g of active substance are mixed with 500 g of corn oil, whereupon the mixture is filled in soft gelatine capsules, each capsule containing 100 mg of the mixture.

Example 9

Preparation of tablets

0.5 kg of active substance are mixed with 0.2 kg of silicic acid of the trademark Aerosil. Potato starch (0.45 kg) and lactose (0.5 kg) are mixed therewith and the mixture is moistened with a starch paste prepared from 50 g of potato starch and distilled water, whereupon the mixture is granulated through a sieve. The granulate is dried and sieved, whereupon 20 g of magnesium stearate are mixed into it. Finally the mixture is pressed into tablets each weighing 172 mg.

Example 10

Preparation of a syrup

100 g of active substance are dissolved in 300 g of 95% ethanol, whereupon 300 g of glycerol, aroma and coloring agents (q.s.) and 1000 ml of water are mixed therein. A syrup is obtained.

Example 11

Preparation of an injection solution

Active substance (1 g), sodium chloride (0.8 g) and ascorbic acid (0.1 g) are dissolved in sufficient amount of distilled water to give 100 ml of solution. This solution, which contains 10 mg of active substance per ml, is used in filling ampoules, which are sterilized by heating at 120°C for 20 minutes.

Example 12

(+)-R-8-Methoxy-2-(di-cyclopropyl-methylamino)tetralin

The resolution is performed on 8-methoxy-2-(benzylamino)tetralin with the aid of (-)-di-p-toluoyltartaric acid according to Karlsson, et al., Acta Chem. Scand., B 42, 231-236 (1988). The enantiomers of 8-methoxy-2-(benzylamino)tetralin are debenzylated, yielding the corresponding enantiomers of 8-methoxy-2-aminotetralin, i.e., R-(+)- and S-(-)-8-methoxy-2-aminotetralin.

The primary amine (+)-R-8-methoxy-2-aminotetralin (3.29 g) is acylated with cyclopropanecarboxylic acid chloride (1.8 ml) and the amide produced (3.63 g) is reduced with QBH₄ as described in above, yielding the

secondary amine, which is acylated again in the same way with cyclopropanecarboxylic acid chloride (3.2 ml). The amide produced (3.57 g) is dissolved in dry THF (25 ml) and reduced with LiAlH_4 at room temperature. Usual workup yields the raw tertiary amine product (2.9 g), which is chromatographed (SiO_2 ; eluting with CH_2Cl_2 :MeOH (19:1)), yielding pure product (2.1 g) as an oil, which is converted to its hydrochloride with HCl-saturated EtOH and evaporation of the solvent and excess acid. No crystals are obtained in an attempt to crystallize the product. The optical rotation is: $\alpha_D^{22} = +68^\circ$ (c 1.0, MeOH).

GC/MS shows M^+ at $m/e=285$ (61%) and the base peak at $m/e=136$. Other prominent peaks appear at $m/e=244$ (30%), 161 (72%) and $m/e=160$ (42%).

10 Example 13

(-)-R-8-Methoxy-2-(di-cyclopropylmethylamino)tetralin

The primary amine (-)-R-8-methoxy-2-aminotetralin (5.0 g) is converted into the secondary amine (-)-R-8-methoxy-2-(cyclopropylmethylamino)tetralin, which is further converted into the tertiary amine (-)-R-8-methoxy-2-(di-cyclopropylmethylamino)tetralin (2.42 g) as described for the corresponding (+)-enantiomer in Example 3 above. The optical rotation is: $\alpha_D^{22} = -66^\circ$ (c 1.0, MeOH).

GC/MS shows M^+ at $m/e=285$ (83%) and the base peak at $m/e=136$. Other prominent peaks appear at $m/e=244$ (33%), 161 (67%) and $m/e=160$ (40%).

20 Example 14

8-Methoxy-2-(N-cyclopropylmethyl-N-ethylamino)tetralin

8-Methoxy-2-(cyclopropylmethylamino)tetralin (200 mg) is dissolved in CH_2Cl_2 (25 ml) and the solution is basified by the addition of Et_3N (3 ml). Acetylchloride (150 μl) is added and the reaction mixture is left stirring for 3 hours. 10% Na_2CO_3 is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 210 mg of the amide as an oil, which is dissolved in dry ether (10 ml). This solution is added to a suspension of LiAlH_4 (0.3 g) in dry ether (10 ml) and the temperature is kept at about 0°C with an ice bath. Usual workup (0.3 ml water, 0.3 ml 15% NaOH, 0.9 ml water, filtration and ether extraction) gives 188 mg of an oil, which is chromatographed (200 g SiO_2 ; eluting with CH_2Cl_2 : MeOH (19:1)), yielding the product as an oil (66 mg).

GC/MS shows M^+ at $m/e=259$ (70%) and the base peak at $m/e=161$. Other prominent peaks appear at $m/e=244$ (33%) and $m/e=160$ (30%).

35 Example 15

8-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin

8-methoxy-2-(n-propylamino)tetralin (350 mg) is dissolved in CH_2Cl_2 (20 ml) and Et_3N (1 ml) and cyclopropanecarboxylic acid chloride (0.5 ml) are added. Workup gives the amide (0.6 g) as an oil. The amide is dissolved in dry ether and reduced with LiAlH_4 (0.9 g). The reaction is quenched after 2 hours in the usual way (0.9 ml H_2O , 0.9 ml 15% NaOH and 2.7 ml H_2O) and workup yields an oil, which is chromatographed on SiO_2 (70 g), eluting with petroleumether:ether (1:1). The fractions containing pureproduct are pooled and the solvent is evaporated yielding an oil (210 mg) which is converted to the hydrochloride with HCl-saturated EtOH and evaporation of the solvent. Crystals (170 mg) are obtained from acetone: ether, and they melt at $143-145^\circ\text{C}$.

GC/MS shows M^+ at $m/e=273.15$ (24.5%) and the base peak at $m/e=161.05$. Other prominent peaks appear at $m/e=245.05$ (14.3%), $m/e=244.05$ (87.1%) and $m/e=162.05$ (18.8%).

50 Example 16

7-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin

7-Methoxy-2-(n-propylamino)tetralin (500 mg) is dissolved in CH_2Cl_2 (25 ml) and the solution is basified by the addition of Et_3N (3 ml). Cyclopropanecarboxylic acid chloride (195 μl) is added and the reaction mixture is left stirring for 4 hours. 10% Na_2CO_3 is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 500 mg of the amide (GC/MS shows M^+ at $m/e=287.15$ (0.3%) and the base peak at $m/e=160.10$) as an oil, which is dissolved in 1,2-dichloro-

ethane (50 ml). To this solution is added QBH₄ (where Q means tetrabutylammonium) (5.0 g) dissolved in CH₂Cl₂ (50 ml). The reaction mixture is refluxed for 36 hours and is then chilled to room temperature and extracted with water several times. The solvents of the organic phase are evaporated and to the residue is added ether. The ether phase is washed with water several times, separated, dried (Na₂SO₄), filtered and the solvent is evaporated to give 453 mg of an oil, which is chromatographed (200 g SiO₂; eluting with petroleumether:ether (9:1), yielding the product as an oil. This oil is converted to the hydrochloride with HCl-saturated EtOH and evaporation to yield an oil (436 mg).

GC/MS shows M⁺ at m/e=273.15 (27.1%) and the base peak at m/e=244.15. Other prominent peaks appear at m/e=161.10 (76.9%).

Example 17

8-Methoxy-2-(N-cyclopropylmethyl-N-(2-thiophenethyl)-amino)tetralin

8-Methoxy-2-aminotetralin (800 mg) is stirred in a two phase system (10% Na₂CO₃ and CH₂Cl₂) and 2-thiopheneacetic acid chloride (1 g) is added. The reaction mixture is stirred for 2 hours and then the organic phase is separated, dried (Na₂SO₄) and filtered. The solvent is evaporated to give the amide as an oil (1.5 g). The amide is reduced with QBH₄ (1 g) in a refluxing (8 hours) mixture of CH₂Cl₂ (50 ml) and 1,2-dichloroethane (50 ml). The reaction mixture is chilled to room temperature and the organic layer is washed several times with water. The organic layer is separated and the solvents are evaporated, yielding an oil, which is treated with EtOAc and water. This mixture is acidified with HCl (10%) and stirred for 30 minutes and then the mixture is basified. The organic layer is separated, dried (Na₂SO₄) and filtered. The solvent is evaporated to give the amine as an oil (900 mg). This oil (400 mg) is dissolved in CH₂Cl₂ (25 ml) and Et₃N (1 ml) and cyclopropanecarboxylic acid chloride (1.0 ml) is added and the reaction mixture is left stirring for one hour. 10% Na₂CO₃ is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 600 mg of the amide as an oil, which is chromatographed (SiO₂ and eluting with petroleumether: ether (2:1)), yielding 270 mg of the pure amide. This amide (270 mg) is dissolved in 1,2-dichloroethane (20 ml). To this solution is added QBH₄ (where Q means tetraethylammonium) (1.0 g) dissolved in CH₂Cl₂ (20 ml). The reaction mixture is refluxed for 12 hours and is then chilled to room temperature and extracted with water several times. The solvents of the organic phase are evaporated and to the residue is added EtOAc (20 ml). The organic phase is washed with water several times, separated, dried (Na₂SO₄), filtered and the solvent is evaporated to give 220 mg of an oil, which is chromatographed (20 g SiO₂; eluting with petroleumether:ether (1:1)), yielding the product as an oil (160 mg). This oil is converted to the hydrochloride with HCl-saturated EtOH and evaporation of the solvent to yield an oil (170 mg).

GC/MS shows M⁺ at m/e=340.20 (0.1%), m/e=341.10 (0.1%), and the base peak at m/e= 161.10. Other prominent peaks appear at m/e=245.20 (11.6%) and m/e=244.20 (63.8%).

Example 18

5-Methoxy-2-(cyclopropylmethylamino)tetralin

5-methoxy-2-aminotetralin (972 mg) is dissolved in CH₂Cl₂ (20 ml) and Et₃N (3 ml) is added together with cyclopropanecarboxylic acid chloride (550 µl). The reaction mixture is left stirring for one hour. 10% Na₂CN₃ is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 1.16 g of the amide as an oil, which is chromatographed (SiO₂ and eluting with CH₂Cl₂:MeOH (45:1)), yielding 0.98 mg of the pure amide (GC/MS shows M⁺ at m/e=245 (61%) and the base peak at m/e=160. Other prominent peaks appear at m/e=159 (26%), m/e=145 (19%) and m/e=129 (18%)). This amide (0.98 g) is dissolved in 1,2-dichloroethane (30 ml). To this solution is added QBH₄ (where Q means tetrabutylammonium) (2.0 g) dissolved in CH₂Cl₂ (30 ml). The reaction mixture is refluxed for 24 hours and then chilled to room temperature and extracted with water several times. The solvents of the organic phase are evaporated and to the residue is added EtOAc (20 ml). The organic phase is washed with water several times, separated, dried (Na₂SO₄), filtered and the solvent is evaporated to give 800 mg of an oil, which is chromatographed (200 g SiO₂; eluting with CH₂Cl₂:MeOH (19:1)), yielding the product as an oil (800 mg).

GC/MS shows M⁺ as the base peak at m/e=231. Other prominent peaks appear at m/e=161 (62%), m/e=160 (83%), m/e=159 (64%), and m/e=104 (92%).

Example 19

5-Methoxy-2-(dicyclopropylmethylamino)tetralin

5 5-Methoxy-2-(cyclopropylmethylamino)tetralin (410 mg) is dissolved in CH_2Cl_2 (20 ml) and Et_3N (3 ml) is added together with cyclopropanecarboxylic acid chloride (400 μl). The reaction mixture is left stirring for 48 hours. 10% Na_2CO_3 is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 520 of the amide as an oil. This raw amide (520 mg) is dissolved in dry THF (15 ml) and this solution is added dropwise to a suspension of LiAlH_2 (0.5 g) in dry THF (10 ml). The reaction mixture is stirred at room temperature for one hour and usual workup gives 385 mg of the desired product as an oil (GC/MS shows M^+ at $m/e=285.20$ (40%), base peak at $m/e=136.05$. Other prominent peaks appear at $m/e=244.10$ (30.1%), $m/e=161.05$ (37.9%, $m/e=$), $m/e=160.15$ (30.2%), and $m/e=159.05$ (13.2%). The product is converted to a crystalline hydrochloride and crystals, melting at 150-153°C, are obtained from EtOH: ether.

Example 20

5-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin

20 5-Methoxy-2-(cyclopropylmethylamino)tetralin (390 mg) is dissolved in CH_2Cl_2 (20 ml) and Et_3N (3 ml) is added together with propionic acid chloride (300 μl). The reaction mixture is left stirring for 5 hours. 10% Na_2CO_3 is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 469 mg of the amide as an oil. This raw amide (469 mg) is dissolved in dry ether (15 ml) and this solution is added dropwise to a suspension of LiAlH_4 (0.45 g) in dry ether (10 ml). The reaction mixture is stirred at room temperature for one hour and usual workup gives 324 mg of the desired product as an oil, which is chromatographed (SiO_2 and eluting with $\text{CH}_2\text{Cl}_2:\text{MeOH}$ (19:1), yielding 201 mg of the desired product as an oil. GC/MS shows M^+ at $m/e=273.20$ (25.0%), base peak at $m/e=244.25$. Other prominent peaks appear at $m/e=245.25$ (18.6%), $m/e=244.05$ (87.1%) and $m/e=161.15$ (75.3%).

Example 21

(+)-cis-1S,2R-5-Methoxy-1-methyl-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin

35 (+)-cis-1S,2R-5-Methoxy-1-methyl-2-(n-propylamino)tetralin (500 mg) is dissolved in CH_2Cl_2 (20 ml) and Et_3N (3 ml) is added together with cyclopropanecarboxylic acid chloride (300 μl). The reaction mixture is left stirring for one hour. 10% Na_2CO_3 is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 550 mg of the amide as an oil. This raw amide (550 mg) is dissolved in dry ether (15 ml) and this solution is added dropwise to a suspension of LiAlH_4 (0.60 g) in dry ether (10 ml). The reaction mixture is stirred at room temperature overnight and usual workup gives 483 mg of the desired product as an oil, which is chromatographed (100 g SiO_2 and eluting with hexane:ether (3:1)), yielding the desired product as an oil (280 mg). This oil is converted to the hydrochloride salt, but no crystals are achieved.

45 GC/MS shows M^+ at $m/e=287.15$ (25.8%) and the base peak at $m/e=258.15$. Other prominent peaks appear at $m/e=259.15$ (19.5%), $m/e=176.10$ (12.4%), $m/e=175.10$ (88.6%) and $m/e=174.20$ (17.4%). The optical rotation is measured and found to be: $\alpha_D^{22}=+38^\circ$ (c 1.0, MeOH).

Example 22

(+)-cis-1S,2R-5-Methoxy-1-methyl-2-(cyclopropylmethylamino)tetralin

50 (+)-cis-1S,2R-5-Methoxy-1-methyl-2-aminotetralin (970 mg) is dissolved in CH_2Cl_2 (20 ml) and Et_3N (3 ml) is added together with cyclopropanecarboxylic acid chloride (500 μl). The reaction mixture is left stirring for one hour. 10% Na_2CO_3 is added and the raw amide product is extracted to the organic layer, which is dried and filtered. The organic solvent is removed by evaporation yielding 1.0 g of the amide as an oil. This raw amide (1.0 g) is dissolved in 1,2-dichloroethane (60 ml). To this solution is added QBH_4 (where Q means tetrabutylammonium) (1.4 g) dissolved in CH_2Cl_2 (60 ml). The reaction mixture is refluxed for 48 hours and is then chilled to room temperature and extracted with water several times. The solvents of the organic phase are evaporated and to the residue is added trichloroethylene. The organic phase is washed with water several times, separated,

dried (Na_2SO_4), filtered and the solvent is evaporated to give 840 mg of an oil, which is converted to the hydrochloride with HCl-saturated EtOH and evaporation to yield crystals (750 mg) melting at 212°C .

GC/MS shows M^+ at $m/e=245.15$ (53.5%) and the base peak at $m/e=148.10$. Other prominent peaks appear at $m/e=190.20$ (15.6%), $m/e=175.10$ (18.2%), $m/e=174.10$ (44.8%), $m/e=173.20$ (10.3%) and $m/e=159.10$ (45.9%). The optical rotation is measured and found to be: $\alpha_D^{22}=+49.1^\circ$ (c 1.0, MeOH).

Example 23

(+)-cis-1S,2R-5-Methoxy-1-methyl-2-(N-cyclopropylmethyl-N-(3-methoxyphenylethyl)amino)tetralin

(+)-cis-1S,2R-5-Methoxy-1-methyl-2-(cyclopropylmethylamino)-tetralin (50 mg) was dissolved in CH_2Cl_2 (5 ml) and 10% NaOH (5 ml) was added together with 3-methoxyphenylacetic acid chloride (50 μl). The reaction mixture was left stirring for one hour. The raw amide product was extracted to the organic layer, which was dried and filtered. The organic solvent was removed by evaporation yielding 60 mg of the amide as an oil. This raw amide (60 mg) was dissolved in 1,2-dichloroethane (10 ml). To this solution was added QBH_4 (where Q means tetraethylammonium) (200 mg) dissolved in CH_2Cl_2 (30 ml). The reaction mixture was refluxed overnight and was then chilled to room temperature and extracted with water several times, separated, dried (Na_2SO_4), filtered and the solvent was evaporated to give 60 mg of the desired product as an oil, which was chromatographed (15 g SiO_2 and eluting with hexane:ether (3:1)), yielding the desired product as an oil (20 mg). This oil was converted to the hydrochloride salt, but no crystals were achieved.

GC/MS shows M^+ at $m/e=379.20$ (0.1%) and the base peak at $m/e=258.20$. Other prominent peaks appeared at $m/e=259.20$ (19.0%), $m/e=176.10$ (8.6%) and $m/e=175.10$ (65.3%). The optical rotation was measured and was found to be $\alpha_D^{22}=+35^\circ$ (c 1.0, MeOH).

Example 24

(+)-R-8-Methoxy-2-(N-cyclopropylmethyl-N-(3-methoxyphenylethyl)amino)- tetralin

(+)-R-8-Methoxy-1-methyl-2-(cyclopropylmethylamino)tetralin (250 mg) was dissolved in CH_2Cl_2 (25 ml) and 10% NaOH (25 ml) was added together with a 3-methoxyphenylacetic acid chloride (0.4 g). The reaction mixture was left stirring for 2 days. The raw amide product was extracted to the organic layer, which was dried and filtered. The organic solvent was removed by evaporation yielding 400 mg of the amide as an oil. This raw amide was chromatographed (SiO_2 and eluting with petroleumether:ether (3:1)). The fractions containing pure product were pooled and the solvent was evaporated yielding an oil (250 mg). The amide oil (250 mg) was dissolved in dry ether (10 ml). To this solution was added LiAlH_4 (100 mg). Usual workup gave the desired product as an oil (100 mg).

GC/MS showed M-1 at $m/e=364.15$ (0.1%) and the base peak at $m/e=161.00$. Other prominent peaks appeared at $m/e=245.05$ (16.2%) and $m/e=244.05$ (87.2%).

Example 25

7-Methylthio-2-(N-cyclopropylmethyl(-N-n-propylamino)-tetralin

7-Bromo-2-(di-n-propylamin)tetralin HCl (600 mg) was converted to the base with 10% Na_2CO_3 and extraction with CH_2Cl_2 . The organic layer was dried and filtered and the solvent was evaporated under reduced pressure. The residual oil was dissolved in dry THF (40 ml) and poured into a flask equipped with $\text{N}_2(g)$ inlet, a drug funnel, a thermometer and septum for syringe injections of reagents and sample collection. This flask was chilled to -78°C and n-BuLi in hexane (1.4M, 3 ml) was injected through the septum. The reaction mixture was stirred for 0.5 hour for the halogen-lithium exchange to take place. This was checked with a small sample quenched in water and GC analysis. Dimethylsulfide (0.5 ml) was added dropwise from the funnel during 30 minutes at -78°C . The $\text{CO}_2(s)$ -bath was removed and the temperature was allowed to reach room temperature before the reaction was quenched with water. Extractive workup yielded an oil (700 mg), which contained 2-(di-n-propylamino)tetralin and the desired product in an approximative ration of 45:55. This raw oil was chromatographed and the fractions containing pure product were pooled and the solvent was evaporated yielding 110 mg of the product as an oil, which was used in the next step without further purification. The oil (95 mg) was dissolved in CH_2Cl_2 (10 ml) and excess Br_2 (35 μl) was added. The organic phase was extracted with 10 % Na_2CO_3 and separated. Excess Br_2 was removed with the addition of anisole (1 ml). The product in the organic phase was then extracted to 10% HCl and the acidic organic phase (containing the brominated anisoles)

was discarded. The acidic water was basified (10% Na₂CO₃) and extracted with ether, dried (Na₂CO₃), filtered and the solvent was evaporated, yielding 40 mg of an oil.

GC/MS showed M⁺ at m/e=235 (60%) and the base peak at m/e=129. Other prominent peaks appeared at m/e=206 (52%), m/e=192 (20%), m/e=177 (45%), m/e=176 (30%), m/e=175 (15%), m/e=151 (25%), m/e=150 (35%) and m/e=130 (50%).

The secondary amine produced (40 mg, 0.17 mmol) was dissolved in CH₂Cl₂ (5 ml) N-acylated with cyclopropanecarboxylic acid chloride (23 µl) in the presence of Et₃N (50 µl). After 30 minutes the reaction mixture was washed with 10% Na₂CO₃ and the organic phase was separated, dried (Na₂CO₃), filtered and the solvent was evaporated, yielding 55 mg of an oil.

GC/MS showed M⁺ at m/e=303 (1%) and the base peak at m/e=176. Other prominent peaks appeared at m/e=175 (15%), m/e=129 (45%) and 128 (25%).

The amide (55 mg) was dissolved in dry ether (10 ml) and reduced by the addition of LiAlH₂ (75 mg). Usual workup gave the raw product as an oil (29 mg), which was chromatographed (SiO₂ and eluting with petroleumether:ether (3:1)). The fraction containing the desired, pure 7-methylthio-2-N-cyclopropylmethyl-N-n-propylamin)tetralin were pooled and the solvent was evaporated, yielding 14 mg of an oil.

GC/MS showed M⁺ at m/e=289 (35%) and the base peak at m/e=260. Other prominent peaks appeared at m/e=261 (20%), m/e=324 (10%), m/e=177 (25%), m/e=176 (10%), m/e=151 (10%), m/e=130 (40%), m/e=129 (45%), m/e=124 (20%) and m/e=84 (15%).

Example 26

(+)-R-8-Methoxy-2-(N-cyclopropylmethyl-N-ethylamino)-tetralin

(+)-R-8-Methoxy-2-(cyclopropylmethylamino)tetralin (500 mg) was dissolved in CH₂Cl₂ (25 ml) and 10% Na₂CO₃ (25 ml) was added together with acetyl chloride (0.4 g). The reaction mixture was left stirring for 2 hours. The raw amide product was extracted to the organic layer, which was dried and filtered. The organic solvent was removed by evaporation yielding the amide as an oil. This raw amide was chromatographed SiO₂ and eluting with petroleumether:ether (3.1)). The fractions containing pure product were pooled and the solvent was evaporated yielding an oil (324 mg). The amide oil (324 mg) was dissolved in dry ether (10 ml). To this solution was added LiAlH₂ (300 ml). Usual workup gave the desired product as an oil (290 mg), which was chromatographed (SiO₂ and eluting with CH₂Cl₂:MeOH (19.1)). The fractions containing pure product were pooled and the solvent was evaporated yielding an oil (153 mg).

GC/MS showed M⁺ at m/e259.15 (70.9%) and the base peak at m/e=161.05. Other prominent peaks appeared at m/e=260.15 (14.2%), m/e=244.15 (32.9%), m/e=218.15 (17.3%), m/e=160.05 (29.7%), m/e=159.05 (14.9%), and m/e=110.05 (80.4%). The optical rotation was measured and was found to be α_D²²=+64.9° (c 1.0, MeOH).

TABLE 1

Screening Data on Newly Synthesized Compounds
Effects on Dopamine (DA) and Serotonin (5-HT) Synthesis Rates
and on Motor Activity in Reserpine Pretreated Rats

Compound	ED50 DOPA ^a		ED50 5-HTP ^b limb	Motor Act ^c	Behavior ^d
	stri	hem			
	(μmol/kg)				
8-OMe-CPMAT ¹					
(sc)	P(16)	I(16)	0.40	+	5-HT syndr
(po)	P(40)	I(40)	3.3	+	5-HT syndr
8-OMe-DCPMAT ²					
(sc)	I(50)	I(50)	1.2	+	5-HT syndr
(po)	I(50)	I(50)	2.0	+	5-HT syndr

¹8-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin

²8-Methoxy-2-(N,N-dicyclopropylmethylamino)tetralin

^aDose giving a half maximal decrease of DOPA formation in the rat striatal or cortical (NA predominated hemispheres) brain parts. The values were estimated from dose-response curves comprising 4 to 6 dose levels (n = 4). Maximal decrease was found to be 80% in striatum and 50% in cortex. Control levels were: striatum 3220 ng/g and cortex 150 ng/g.

^bDose giving a half maximal decrease of 5-HTP formation in the rat limbic brain part. The values were estimated from dose-response curves comprising 4 to 6 dose levels (n = 4). Maximal decrease was found to be 50%. Control level was: 191 ng/g.

"P" denotes partial agonist, i.e., a submaximal decrease in DOPA or 5-HTP formation was noted at the highest dose (shown in brackets in μmol/kg) tested.

^cMotor activity as measured in photocell-equipped motility boxes. "+" and "-" denote activation and no change, respectively, as compared to controls (essentially no locomotion was registered in these controls (reserpinized rats)).

^dThe gross behavior of the animals was observed during the course of the experiments. The 5-HT behavioral syndrome consisted of flat body posture, abducted hind- and forelegs, forepaw treading (piano-playing) and Straub tail.

TABLE 1 (continued)

Screening Data on Newly Synthesized Compounds
Effects on Dopamine (DA) and Serotonin (5-HT) Synthesis Rates
and on Motor Activity in Reserpine Pretreated Rats


Compound	In vitro binding ^e		Bioavailability ^f		
	D2 IC50 nM	5-HT1A IC50 nM	bioch po/sc in %	temp	plasma
8-OMe-CPMAT ¹					
(sc)		6	12	-	-
(po)					
8-OMe-DCPMAT ²					
(sc)	40000	21	60	36	6-16
(po)					

¹8-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin

²8-Methoxy-2-(N,N-dicyclopropylmethylamino)tetralin

^eThe affinity of the test compounds for dopamine D2 receptor sites was determined by calculating the IC50 value (see text).

^f"Bioch" denotes the bioavailability as estimated by comparing the ED50 values after s.c. and p.o. administration (reserpine-pretreated rats). "Temp" denotes the bioavailability as estimated by comparing the decrease in rectal temperature after s.c. (25.0 µmol/kg) and p.o. (100.0 µmol/kg) administration of the test drugs in non-pretreated rats (c.f., Figures 1 and 2). "Plasma" denotes the availability as estimated by comparing plasma drug levels (measured by means of GC/MS) after s.c. and p.o. administration of test drugs in non-pretreated rats.

FORMULA

Formula I

CHART 1

5

10

15

20

25

30

35

40

45

50

55






CHART 1 (continued)



Claims

Claims for the following Contracting States : AT BE CH DE FR GB IT LU NL SE

1. A compound of formula I



wherein either YR₁ is C₁-C₃ alkylthio at the 5, 6, 7 or 8 position of the tetralin nucleus, or YR₁ is OR₁ at

the 7 or 8 position and R_1 is C_1 - C_8 alkyl, C_2 - C_8 alkenyl, $-CH_2-$ (C_3 - C_8 cycloalkyl) or benzyl;


R_2 is hydrogen or C_1 - C_3 alkyl;

R_3 is $-CH_2-$ (C_3 - C_8 cycloalkyl); and

R_4 is hydrogen, C_1 - C_8 alkyl, $-CH_2-$ (C_3 - C_4 cycloalkyl), $-(CH_2)_mR_5$ or $-CH_2-CH_2-X-(CH_2)_nCH_3$; where-
 in n is zero to 3; m is 2 or 3; X is oxygen or sulfur; and R_5 is 2-thiophenyl, 3-thiophenyl, phenyl or phenyl
 substituted by one or two substituents selected from chlorine, bromine, fluorine, C_1 - C_3 alkoxy and C_1 - C_3
 alkyl;


with the proviso that when R_3 contains more than four carbon atoms and R_4 is alkyl, said alkyl con-
 tains from one to 3 carbon atoms;
 or a pharmaceutically-acceptable acid addition salt thereof.

2. Use of a compound of formula Ia



or a pharmaceutically-acceptable acid addition salt thereof, wherein R_1 , R_2 , R_3 and R_4 are as defined in
 claim 1, for the manufacture of a medicament for use as an anxiolytic or anti-depressant, for the treatment
 of panic attacks, obsessive-compulsive disturbances or dementia, or for the mediation of sexual behaviour.

3. Use of a compound of formula Ib




or a pharmaceutically-acceptable acid addition salt thereof, wherein OR_1 is at the 5, 6 or 7 position of the
 tetralin nucleus and R_1 , R_2 , R_3 and R_4 are as defined in claim 1, for the manufacture of a medicament for
 use in the treatment of psychoses, mania-depressive illness and parkinsonism.

4. A compound according to claim 1, wherein YR_1 is OR_1 and R_1 is C_1 - C_8 alkyl or $-CH_2-$ (C_3 - C_8 cycloalkyl).
5. A compound according to claim 4, wherein R_2 is hydrogen.
6. A compound according to claim 5, wherein R_4 is hydrogen, C_1 - C_8 alkyl or $-CH_2-$ (C_3 - C_4 cycloalkyl).
7. A compound according to claim 1, which is 8-methoxy-2-(N-cyclopropylmethyl -N-n-propylamino) tetralin.
8. A compound according to claim 1, which is 8-methoxy-2-[N,N-di-(cyclopropylmethyl)amino]tetralin.
9. A compound according to claim 1, which is 1-methyl-8-methoxy-2-(N-cyclopropylmethyl-N-n-propylami-
 no) tetralin or 1-methyl-8-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.
10. A compound according to claim 1, which is 7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino) tetralin
 or 7-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.
11. A compound according to claim 1, which is 1-methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylami-
 no) tetralin or 1-methyl-7-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.
12. Use according to claim 2 or claim 3, wherein R_1 is C_1 - C_8 alkyl or $-CH_2-$ (C_3 - C_8 cycloalkyl).

13. Use according to claim 12, wherein R_2 is hydrogen.
14. Use according to claim 13, wherein R_4 is hydrogen, C_1 - C_8 alkyl or $-CH_2$ -(C_3 - C_4 cycloalkyl).
15. Use according to claim 2, wherein the compound is as defined in any of claims 7 to 9.
16. Use according to claim 3, wherein R_1 is methyl, R_2 is hydrogen, R_3 is cyclopropylmethyl, and R_4 is cyclopropylmethyl or n-propyl.
17. Use according to claim 3, wherein the compound is 1-methyl-5-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin; 1-methyl-5-methoxy-2-(N,N-dicyclopropylmethylamino)tetralin; 1-methyl-6-methoxy-2-(N-cyclopropylmethylamino)tetralin; 1-methyl-6-methoxy-2-(N,N-dicyclopropylmethylamino)tetralin; 1-methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin; or 1-methyl-7-methoxy-2-(N,N-dicyclopropylmethylamino)tetralin.

Claims for the following Contracting States : ES GR

1. A process for preparing a compound of formula I



wherein either YR_1 is C_1 - C_3 alkylthio at the 5, 6, 7 or 8 position of the tetralin nucleus, or YR_1 is OR_1 at the 7 or 8 position and R_1 is C_1 - C_8 alkyl, C_2 - C_8 alkenyl, $-CH_2$ -(C_3 - C_8 cycloalkyl) or benzyl;

R_2 is hydrogen or C_1 - C_3 alkyl;

R_3 is $-CH_2$ -(C_3 - C_8 cycloalkyl); and

R_4 is hydrogen, C_1 - C_8 alkyl, $-CH_2$ -(C_3 - C_4 cycloalkyl), $-(CH_2)_m-R_5$ or $-CH_2-CH_2-X-(CH_2)_nCH_3$; where-
in n is zero to 3; m is 2 or 3; X is oxygen or sulfur; and R_5 is 2-thiophenyl, 3-thiophenyl, phenyl or phenyl
substituted by one or two substituents selected from chlorine, bromine, fluorine, C_1 - C_3 alkoxy and C_1 - C_3
alkyl;

with the proviso that when R_3 contains more than four carbon atoms and R_4 is alkyl, said alkyl con-
tains from one to 3 carbon atoms;

or a pharmaceutically-acceptable acid addition salt thereof;

which comprises


(i) when YR_1 is OR_1 , alkylating a corresponding compound wherein R_1 and/or R_4 is replaced by H, with
an appropriate alkylating agent;

(ii) when YR_1 is OR_1 and R_4 is not H or CH_3 , reducing with a hydride reducing agent a corresponding
compound wherein R_4 is replaced by COR_d , wherein R_d is C_1 - C_7 alkyl, C_3 - C_8 cycloalkyl (when R_3 is -
 CH_2 -(C_3 - C_4 cycloalkyl)), R_5 , $-(CH_2)_2-R_5$, $-CH_2-X-(CH_2)_n-CH_3$; or

(iii) when YR_1 is alkylthio, lithiating a corresponding compound wherein YR_1 is replaced by Br, using n-
butyllithium in THF or ether, followed by quenching with $(C_1$ - C_3 alkyl)-S-S-(C_1 - C_3 alkyl).

2. A process according to claim 1, wherein YR_1 is OR_1 and R_4 is C_1 - C_8 alkyl or $-CH_2$ -(C_3 - C_8 cycloalkyl).
3. A process according to claim 2, wherein R_2 is hydrogen.
4. A process according to claim 3, wherein R_4 is hydrogen, C_1 - C_8 alkyl or $-CH_2$ -(C_3 - C_4 cycloalkyl).
5. A process according to claim 1, wherein the compound of formula I is 8-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin.
6. A process according to claim 1, wherein the compound of formula I is 8-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.


7. A process according to claim 1, wherein the compound of formula I is 1-methyl-8-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin or 1-methyl-8-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.
8. A process according to claim 1, wherein the compound of formula I is 7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin or 7-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.
9. A process according to claim 1, wherein the compound of formula I is 1-methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin or 1-methyl-7-methoxy-2-[N,N-di(cyclopropylmethyl)amino]tetralin.
10. Use of a compound of formula Ia



I a

or a pharmaceutically-acceptable acid addition salt thereof, wherein R_1 , R_2 , R_3 and R_4 are as defined in claim 1, for the manufacture of a medicament for use as an anxiolytic or anti-depressant, for the treatment of panic attacks, obsessive-compulsive disturbances or dementia, or for the mediation of sexual behaviour.

11. Use of a compound of formula Ib



I b


or a pharmaceutically-acceptable acid addition salt thereof, wherein OR_1 is at the 5, 6 or 7 position of the tetralin nucleus and R_1 , R_2 , R_3 and R_4 are as defined in claim 1, for the manufacture of a medicament for use in the treatment of psychoses, mania-depressive illness and parkinsonism.

12. Use according to claim 10 or claim 11, wherein R_1 is C_1 - C_8 alkyl or $-CH_2$ -(C_3 - C_8 cycloalkyl).
13. Use according to claim 12, wherein R_2 is hydrogen.
14. Use according to claim 13, wherein R_4 is hydrogen, C_1 - C_8 alkyl or $-CH_2$ -(C_3 - C_4 cycloalkyl).
15. Use according to claim 10, wherein the compound is as defined in any of claims 5 to 7.
16. Use according to claim 11, wherein R_1 is methyl, R_2 is hydrogen, R_3 is cyclopropylmethyl, and R_4 is cyclopropylmethyl or n-propyl.
17. Use according to claim 11, wherein the compound is 1-methyl-5-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin; 1-methyl-5-methoxy-2-(N,N-dicyclopropylmethylamino)tetralin; 1-methyl-6-methoxy-2-(N-cyclopropylmethylamino)tetralin; 1-methyl-6-methoxy-2-(N,N-dicyclopropylmethylamino)tetralin; 1-methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin; or 1-methyl-7-methoxy-2-(N,N-dicyclopropylmethylamino)tetralin.

Patentansprüche

Patentansprüche für folgende Vertragstaaten : AT, BE, CH, DE, FR, BG, IT, LU, NL, SE


1. Eine Verbindung der Formel I



worin bedeuten:


- YR₁ entweder C₁-C₃-Alkylthio in 5-, 6-, 7- oder 8-Stellung des Tetralinkerns oder OR₁ in 7- oder 8-Stellung mit R₁ gleich C₁-C₈-Alkyl, C₂-C₈-Alkenyl, -CH₂-(C₃-C₈-Cycloalkyl) oder Benzyl;
 R₂ Wasserstoff oder C₁-C₃-Alkyl;
 R₃ -CH₂-(C₃-C₈-Cycloalkyl) und
 R₄ Wasserstoff, C₁-C₈-Alkyl, -CH₂-(C₃-C₄-Cycloalkyl), -(CH₂)_m-R₅ oder -CH₂-CH₂-X-(CH₂)_nCH₃, mit n = 0 bis 3; m = 2 oder 3; X gleich Sauerstoff oder Schwefel und R₅ gleich 2-Thiophenyl, 3-Thiophenyl, Phenyl oder ein- oder zweifach chlor-, brom-, fluor-, C₁-C₃-alkoxy- oder C₁-C₃-alkylsubstituiertem Phenyl, wobei gilt, daß im Falle, daß R₃ mehr als 4 Kohlenstoffatome aufweist und R₄ für Alkyl steht, dieses Alkyl 1 bis 3 Kohlenstoffatom(e) enthält;
 oder ein pharmazeutisch akzeptables Säureadditionssalz derselben.

2. Verwendung einer Verbindung der Formel Ia



oder eines pharmazeutisch akzeptablen Säureadditionssalzes derselben, worin R₁, R₂, R₃ und R₄ die in Anspruch 1 angegebene Bedeutung besitzen, für die Herstellung eines Arzneimittels zur Verwendung als Anxiolytikum oder Antidepressivum, zur Behandlung von Panikanfällen, von zwangsneurotischen-zwanghaften Störungen oder Schwachsinn oder zur Vermittlung eines Sexualverhaltens.

3. Verwendung einer Verbindung der Formel Ib




oder eines pharmazeutisch akzeptablen Säureadditionssalzes derselben, worin OR₁ sich in 5-, 6- oder 7-Stellung des Tetralinkerns befindet und R₁, R₂, R₃ und R₄ die in Anspruch 1 angegebene Bedeutung besitzen, zur Herstellung eines Arzneimittels zur Verwendung bei der Behandlung von Psychosen, manisch-depressiver Erkrankung und Parkinsonismus.

4. Verbindung nach Anspruch 1, worin YR₁ für OR₁ steht und R₁ C₁-C₈-Alkyl oder -CH₂-(C₃-C₈-Cycloalkyl) ist.

5. Verbindung nach Anspruch 4, worin R_2 für Wasserstoff steht.
6. Verbindung nach Anspruch 5, worin R_4 für Wasserstoff, C_1 - C_8 -Alkyl oder $-CH_2-(C_3-C_4\text{-Cycloalkyl})$ steht.
7. Verbindung nach Anspruch 1, nämlich 8-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin.
8. Verbindung nach Anspruch 1, nämlich 8-Methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]-tetralin.
9. Verbindung nach Anspruch 1, nämlich 1-Methyl-8-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin oder 1-Methyl-8-methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]tetralin.
10. Verbindung nach Anspruch 1, nämlich 7-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin oder 7-Methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]-tetralin.
11. Verbindung nach Anspruch 1, nämlich 1-Methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin oder 1-Methyl-7-methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]tetralin.
12. Verwendung nach Anspruch 2 oder 3, worin R_1 für C_1 - C_8 -Alkyl oder $-CH_2-(C_3-C_8\text{-Cycloalkyl})$ steht.
13. Verwendung nach Anspruch 12, worin R_2 für Wasserstoff steht.
14. Verwendung nach Anspruch 13, worin R_4 für Wasserstoff, C_1 - C_8 -Alkyl oder $-CH_2-(C_3-C_4\text{-Cycloalkyl})$ steht.
15. Verwendung nach Anspruch 2, wobei die Verbindung der Definition nach einem der Ansprüche 7 bis 9 entspricht.
16. Verwendung nach Anspruch 3, worin R_1 Methyl darstellt, R_2 Wasserstoff bedeutet, R_3 für Cyclopropylmethyl steht und R_4 Cyclopropylmethyl oder n-Propyl entspricht.
17. Verwendung nach Anspruch 3, wobei die Verbindung 1-Methyl-5-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin; 1-Methyl-5-methoxy-2-(N,N-dicyclopropylmethylamino)-tetralin; 1-Methyl-6-methoxy-2-(N-cyclopropylmethylamino)-tetralin; 1-Methyl-6-methoxy-2-(N,N-dicyclopropylmethylamino)-tetralin; 1-Methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin oder 1-Methyl-7-methoxy-2-(N,N-dicyclopropylmethylamino)-tetralin ist.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer Verbindung der Formel I



worin bedeuten:

YR_1 entweder C_1 - C_3 -Alkylthio in 5-, 6-, 7- oder 8-Stellung des Tetralinkerns oder OR_1 in 7- oder 8-Stellung mit R_1 gleich C_1 - C_8 -Alkyl, C_2 - C_8 -Alkenyl, $-CH_2-(C_3-C_8\text{-Cycloalkyl})$ oder Benzyl;

R_2 Wasserstoff oder C_1 - C_3 -Alkyl;

R_3 $-CH_2-(C_3-C_8\text{-Cycloalkyl})$ und

R_4 Wasserstoff, C_1 - C_8 -Alkyl, $-CH_2-(C_3-C_4\text{-Cycloalkyl})$, $-(CH_2)_m-R_5$ oder $-CH_2-CH_2-X-(CH_2)_nCH_3$, mit $n = 0$ bis 3; $m = 2$ oder 3; X gleich Sauerstoff oder Schwefel und R_5 gleich 2-Thiophenyl, 3-Thiophenyl, Phenyl oder ein- oder zweifach chlor-, brom-, fluor-, C_1 - C_3 -alkoxy- oder C_1 - C_3 -alkylsubstituiertem Phenyl, wobei gilt, daß im Falle, daß R_3 mehr als 4 Kohlenstoffatome aufweist und R_4 für Alkyl steht, dieses Alkyl 1 bis 3 Kohlenstoffatom(e) enthält;

oder eines pharmazeutisch akzeptablen Säureadditionssalzes derselben, dadurch gekennzeichnet, daß man

(I) wenn $YR_1 = OR_1$ eine entsprechende Verbindung, worin R_1 und/oder R_4 durch H ersetzt ist (sind),

mit einem geeigneten Alkylierungsmittel alkyliert;

(II) wenn $YR_1 = OR_1$ und R_4 nicht für H oder CH_3 steht, eine entsprechende Verbindung, worin R_4 durch COR_4 mit R_4 gleich C_1 - C_7 -Alkyl, C_3 - C_8 -Cycloalkyl (wenn $R_3 = -CH_2-(C_3-C_4\text{-Cycloalkyl})$), R_5 , $-(CH_2)_2-R_5$ oder $-CH_2-X-(CH_2)_n-CH_3$ ersetzt ist, mit einem Hydrid-reduktionsmittel reduziert; oder

(III) wenn $YR_1 = \text{Alkylthio}$, eine entsprechende Verbindung, worin YR_1 durch Br ersetzt ist, unter Verwendung von *n*-Butyllithium in Tetrahydrofuran oder Ether lithiiert und anschließend mit $(C_1-C_3\text{-Alkyl})-S-S-(C_1-C_3\text{-alkyl})$ abschreckt.

2. Verfahren nach Anspruch 1, worin YR_1 für OR_1 steht und R_1 C_1 - C_8 -Alkyl oder $-CH_2-(C_3-C_8\text{-Cycloalkyl})$ bedeutet.

3. Verfahren nach Anspruch 2, worin R_2 Wasserstoff bedeutet.

4. Verfahren nach Anspruch 3, worin R_4 Wasserstoff, C_1 - C_8 -Alkyl oder $-CH_2-(C_3-C_4\text{-Cycloalkyl})$ bedeutet.

5. Verfahren nach Anspruch 1 zur Herstellung von 8-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin als Verbindung der Formel I.


6. Verfahren nach Anspruch 1 zur Herstellung von 8-Methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]-tetralin als Verbindung der Formel I.

7. Verfahren nach Anspruch 1 zur Herstellung von 1-Methyl-8-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin oder 1-Methyl-8-methoxy-2-[N,N-di-(cyclopropylmethyl)amino]-tetralin als Verbindungen der Formel I.

8. Verfahren nach Anspruch 1 zur Herstellung von 7-Methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin oder 7-Methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]-tetralin als Verbindungen der Formel I.

9. Verfahren nach Anspruch 1 zur Herstellung von 1-Methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)tetralin oder 1-Methyl-7-methoxy-2-[N,N-di-(cyclopropylmethyl)-amino]-tetralin als Verbindungen der Formel I.


10. Verwendung einer Verbindung der Formel Ia



I a

oder eines pharmazeutisch akzeptablen Säureadditionssalzes derselben, worin R_1 , R_2 , R_3 und R_4 die in Anspruch 1 angegebene Bedeutung besitzen, für die Herstellung eines Arzneimittels zur Verwendung als Anxiolytikum oder Antidepressivum, zur Behandlung von Panikanfällen, von zwangsneurotischen-zwanghaften Störungen oder Schwachsinn oder zur Vermittlung eines Sexualverhaltens.

11. Verwendung einer Verbindung der Formel Ib



I b

oder eines pharmazeutisch akzeptablen Säureadditionssalzes derselben, worin OR_1 sich in 5-, 6- oder 7- Stellung des Tetralinkerns befindet und R_1 , R_2 , R_3 und R_4 die in Anspruch 1 angegebene Bedeutung

besitzen, zur Herstellung eines Arzneimittels zur Verwendung bei der Behandlung von Psychosen, manisch-depressiver Erkrankung und Parkinsonismus.

12. Verwendung nach Anspruch 10 oder 11, worin R_1 für C_1 - C_8 -Alkyl oder $-CH_2$ -(C_3 - C_8 -Cycloalkyl) steht.

13. Verwendung nach Anspruch 12, worin R_2 für Wasserstoff steht.

14. Verwendung nach Anspruch 13, worin R_4 für Wasserstoff, C_1 - C_8 -Alkyl oder $-CH_2$ -(C_3 - C_4 -Cycloalkyl) steht.

15. Verwendung nach Anspruch 10, wobei die Verbindung der Definition nach einem der Ansprüche 5 bis 7 entspricht.


16. Verwendung nach Anspruch 11, worin R_1 Methyl darstellt, R_2 Wasserstoff bedeutet, R_3 für Cyclopropylmethyl steht und R_4 Cyclopropylmethyl oder n-Propyl entspricht.

17. Verwendung nach Anspruch 11, wobei die Verbindung 1-Methyl-5-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin; 1-Methyl-5-methoxy-2-(N,N-dicyclopropylmethylamino)-tetralin; 1-Methyl-6-methoxy-2-(N-cyclopropylmethylamino)-tetralin; 1-Methyl-6-methoxy-2-(N,N-dicyclopropylmethylamino)-tetralin; 1-Methyl-7-methoxy-2-(N-cyclopropylmethyl-N-n-propylamino)-tetralin oder 1-Methyl-7-methoxy-2-(N,N-dicyclopropylmethylamino)-tetralin ist.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

1. Composé de formule I



I

dans laquelle YR_1 est un groupe alkylthio en C_1 à C_3 en position 5, 6, 7 ou 8 du noyau de tétraline, ou bien YR_1 est un groupe OR_1 en position 7 ou 8 et R_1 est un groupe alkyle en C_1 à C_8 , alcényle en C_2 à C_8 , $-CH_2$ -(cycloalkyle en C_3 à C_8) ou benzyle ;

R_2 est l'hydrogène ou un groupe alkyle en C_1 à C_3 ;


R_3 est un groupe $-CH_2$ -(cycloalkyle en C_3 à C_8) ; et

R_4 est l'hydrogène, un groupe alkyle en C_1 à C_8 , $-CH_2$ -(cycloalkyle en C_3 ou C_4), $-(CH_2)_m-R_5$ ou $-CH_2-CH_2-X-(CH_2)_n-CH_3$; n a une valeur de zéro à 3 ; m a la valeur 2 ou 3 ; X est l'oxygène ou le soufre ; et R_5 est un groupe 2-thiophényle, 3-thiophényle, phényle ou phényle substitué par un ou deux substituants choisis entre le chlore, le brome, le fluor, des radicaux alkoxy en C_1 à C_3 et alkyle en C_1 à C_3 ;

sous réserve que lorsque R_3 contient plus de quatre atomes de carbone et R_4 est un groupe alkyle, ledit groupe alkyle contienne 1 à 3 atomes de carbone ;

ou un sel d'addition d'acide pharmaceutiquement acceptable de ce composé.


2. Utilisation d'un composé de formule Ia



Ia

ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé, formule dans laquelle R_1 , R_2 , R_3 et R_4 sont tels que définis dans la revendication 1, pour la préparation d'un médicament destiné à être utilisé comme anxiolytique ou anti-dépresseur, pour le traitement de crises paniques, de troubles par obsession-compulsion ou de la démence, ou pour la médiation du comportement sexuel.

3. Utilisation d'un composé de formule Ib




ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé, formule dans laquelle OR_1 est en position 5, 6 ou 7 du noyau de tétraline et R_1 , R_2 , R_3 et R_4 sont tels que définis dans la revendication 1, pour la préparation d'un médicament destiné à être utilisé dans le traitement de psychoses, de la maladie mano-dépressive et de la maladie de Parkinson.

4. Composé suivant la revendication 1, dans lequel YR_1 est un groupe OR_1 et R_1 est un groupe alkyle en C_1 à C_8 ou $-CH_2-$ (cycloalkyle en C_3 à C_8).
5. Composé suivant la revendication 4, dans lequel R_2 est l'hydrogène.
6. Composé suivant la revendication 5, dans lequel R_4 est l'hydrogène, un groupe alkyle en C_1 à C_4 ou un groupe $-CH_2-$ (cycloalkyle en C_3 ou C_4).
7. Composé suivant la revendication 1, qui est la 8-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline.
8. Composé suivant la revendication 1, qui est la 8-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.
9. Composé suivant la revendication 1, qui est la 1-méthyl-8-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline ou la 1-méthyl-8-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.
10. Composé suivant la revendication 1, qui est la 7-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline ou la 7-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.
11. Composé suivant la revendication 1, qui est la 1-méthyl-7-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline ou la 1-méthyl-7-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.
12. Utilisation suivant la revendication 2 ou la revendication 3, dans laquelle R_1 est un groupe alkyle en C_1 à C_8 ou $-CH_2-$ (cycloalkyle en C_3 à C_8).
13. Utilisation suivant la revendication 12, dans laquelle R_2 est l'hydrogène.
14. Utilisation suivant la revendication 13, dans laquelle R_4 est l'hydrogène, un groupe alkyle en C_1 à C_8 ou $-CH_2-$ (cycloalkyle en C_3 ou C_4).
15. Utilisation suivant la revendication 2, dans laquelle le composé est tel que défini dans l'une quelconque des revendications 7 à 9.
16. Utilisation suivant la revendication 3, dans laquelle R_1 est un groupe méthyle, R_2 est l'hydrogène, R_3 est le groupe cyclopropylméthyle et R_4 est le groupe cyclopropylméthyle ou n-propyle.
17. Utilisation suivant la revendication 3, dans laquelle le composé est la 1-méthyl-5-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline, la 1-méthoxy-5-méthoxy-2-(N,N-dicyclopropylméthylamino)tétraline, la 1-méthyl-6-méthoxy-2-(N-cyclopropylméthylamino)tétraline, la 1-méthyl-6-méthoxy-2-(N,N-dicyclopropylméthylamino)tétraline, la 1-méthyl-7-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétrali-

ne et la 1-méthyl-7-méthoxy-2-(N,N-dicyclopropylméthylamino)tétraline.

Revendications pour les Etats contractants suivants : ES, GR

- 5 1. Procédé de préparation d'un composé de formule I



- 15 dans laquelle YR₁ est un groupe alkylthio en C₁ à C₃ en position 5, 6, 7 ou 8 du noyau de tétraline, ou bien YR₁ est un groupe OR₁ en position 7 ou 8 et R₁ est un groupe alkyle en C₁ à C₈, alcényle en C₂ à C₈ -CH₂-(cycloalkyle en C₃ à C₈) ou benzyle ;

R₂ est l'hydrogène ou un groupe alkyle en C₁ à C₃ ;

R₃ est un groupe -CH₂-(cycloalkyle en C₃ à C₈) ; et

- 20 R₄ est l'hydrogène, un groupe alkyle en C₁ à C₈, -CH₂-(cycloalkyle en C₃ ou C₄), -(CH₂)_m-R₅ ou -CH₂-CH₂-X-(CH₂)_n-CH₃ ; n a une valeur de zéro à 3 ; m a la valeur 2 ou 3 ; X est l'oxygène ou le soufre ; et R₅ est un groupe 2-thiophényle, 3-thiophényle, phényle ou phényle substitué par un ou deux substituants choisis entre le chlore, le brome, le fluor, des radicaux alkoxy en C₁ à C₃ et alkyle en C₁ à C₃ ;

- 25 sous réserve que lorsque R₃ contient plus de quatre atomes de carbone et R₄ est un groupe alkyle, ledit groupe alkyle contienne 1 à 3 atomes de carbone ;

ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé ;

qui consiste

- (i) lorsque YR₁ est un groupe OR₁, à alkyler un composé correspondant dans lequel R₁ et/ou R₄ sont remplacés par H, avec un agent alkylant approprié ;
- 30 (ii) lorsque YR₁ est un groupe OR₁ et R₄ ne représente pas H ou CH₃, à réduire avec un hydrure réducteur un composé correspondant dans lequel R₄ est remplacé par COR_d, où R_d est un groupe alkyle en C₁ à C₇, cycloalkyle en C₃ à C₈ (lorsque R₃ est un groupe -CH₂-(cycloalkyle en C₃ ou C₄)), R₅, -(CH₂)₂-R₅, -CH₂-X-(CH₂)_n-CH₃ ; ou bien
- 35 (iii) lorsque YR₁ est un groupe alkylthio, à introduire du lithium dans un composé correspondant où YR₁ est remplacé par Br, en utilisant le n-butyllithium dans du THF ou dans de l'éther, puis à désactiver avec un composé de formule (alkyle en C₁ à C₃)-S-S-(alkyle en C₁ à C₃).

2. Procédé suivant la revendication 1, dans lequel YR₁ est un groupe OR₁ et R₁ est un radical alkyle en C₁ à C₈ ou -CH₂-(cycloalkyle en C₃ à C₈).

- 40 3. Procédé suivant la revendication 2, dans lequel R₂ est l'hydrogène.

4. Procédé suivant la revendication 3, dans lequel R₄ est l'hydrogène, un groupe alkyle en C₁ à C₈ ou -CH₂-(cycloalkyle en C₃ ou C₄).

- 45 5. Procédé suivant la revendication 1, dans lequel le composé de formule I est la 8-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline.

6. Procédé suivant la revendication 1, dans lequel le composé de formule I est la 8-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.


- 50 7. Procédé suivant la revendication 1, dans lequel le composé de formule I est la 1-méthyl-8-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline ou la 1-méthyl-8-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.

- 55 8. Procédé suivant la revendication 1, dans lequel le composé de formule I est la 7-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline ou la 7-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.

9. Procédé suivant la revendication 1, dans lequel le composé de formule I est la 1-méthyl-7-méthoxy-2-(N-

cyclopropylméthyl-N-n-propylamino)tétraline ou la 1-méthyl-7-méthoxy-2-[N,N-di(cyclopropylméthyl)amino]tétraline.


10. Utilisation d'un composé de formule Ia



I a

ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé, où R_1 , R_2 , R_3 et R_4 sont tels que définis dans la revendication 1, pour la préparation d'un médicament destiné à être utilisé comme anxiolytique ou anti-dépresseur, pour le traitement de crises paniques, de troubles par obsession-compulsion ou de la démence, ou pour la médiation du comportement sexuel.

11. Utilisation d'un composé de formule Ib



I b

ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé, dans lequel OR_1 est en position 5, 6 ou 7 du noyau de tétraline et R_1 , R_2 , R_3 et R_4 sont tels que définis dans la revendication 1, pour la préparation d'un médicament destiné à être utilisé dans le traitement de psychoses, de la maladie mano-dépressive et de la maladie de Parkinson.

12. Utilisation suivant la revendication 10 ou la revendication 11, dans laquelle R_1 est un groupe alkyle en C_1 à C_8 ou $-CH_2-$ (cycloalkyle en C_3 à C_8).

13. Utilisation suivant la revendication 12, dans laquelle R_2 est l'hydrogène.

14. Utilisation suivant la revendication 13, dans laquelle R_4 est l'hydrogène, un groupe alkyle en C_1 à C_8 ou $-CH_2-$ (cycloalkyle en C_3 ou C_4).

15. Utilisation suivant la revendication 10, dans laquelle le composé est tel que défini dans l'une quelconque des revendications 5 à 7.

16. Utilisation suivant la revendication 11, dans laquelle R_1 est un groupe méthyle, R_2 est l'hydrogène, R_3 est un groupe cyclopropylméthyle et R_4 est un groupe cyclopropylméthyle ou n-propyle.

17. Utilisation suivant la revendication 11, dans laquelle le composé est la 1-méthyl-5-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline, la 1-méthyl-5-méthoxy-2-(N,N-dicyclopropylméthylamino)tétraline, la 1-méthyl-6-méthoxy-2-(N-cyclopropylméthylamino)tétraline, la 1-méthyl-6-méthoxy-2-(N,N-dicyclopropylméthylamino)tétraline, la 1-méthyl-7-méthoxy-2-(N-cyclopropylméthyl-N-n-propylamino)tétraline ou la 1-méthyl-7-méthoxy-2-(N,N-dicyclopropylméthylamino)tétraline.